abrdn plc Invests $1.72 Million in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

abrdn plc purchased a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 230,745 shares of the company’s stock, valued at approximately $1,719,000.

A number of other hedge funds have also bought and sold shares of the business. Greenwich Wealth Management LLC raised its position in shares of EyePoint Pharmaceuticals by 8.3% in the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock valued at $93,000 after buying an additional 900 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in EyePoint Pharmaceuticals by 68.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock valued at $82,000 after acquiring an additional 4,172 shares in the last quarter. Cyndeo Wealth Partners LLC lifted its position in shares of EyePoint Pharmaceuticals by 35.5% during the 4th quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company’s stock valued at $127,000 after acquiring an additional 4,450 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of EyePoint Pharmaceuticals by 5.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock worth $1,141,000 after purchasing an additional 7,967 shares in the last quarter. Finally, Woodstock Corp increased its position in shares of EyePoint Pharmaceuticals by 29.1% in the third quarter. Woodstock Corp now owns 71,480 shares of the company’s stock worth $571,000 after purchasing an additional 16,093 shares during the period. 99.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EYPT has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, December 5th. Scotiabank started coverage on shares of EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 price target on the stock. Robert W. Baird lowered their price objective on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Chardan Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, February 6th. Finally, Citigroup initiated coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price target on the stock. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Price Performance

Shares of EYPT opened at $6.27 on Tuesday. EyePoint Pharmaceuticals, Inc. has a 1-year low of $5.90 and a 1-year high of $30.78. The company has a market capitalization of $427.93 million, a P/E ratio of -3.14 and a beta of 1.51. The firm’s 50 day simple moving average is $7.82 and its 200 day simple moving average is $8.77.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.